|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/00 | |
| A61K 31/5377 | |||
| A61K 9/14 | |||
| A61K 9/20 | |||
| A61K 9/48 | |||
| A61K 31/635 |
| (11) | Patento numeris | 3272334 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17181461.9 |
| Europos patento paraiškos padavimo data | 2010-06-08 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-01-24 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-03-06 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 185130 P | 2009-06-08 | US |
| (72) |
PACKHAEUSER, Claudia, DE
STEIGER, Norbert, DE
LIEPOLD, Bernd, DE
KOSTELAC, Drazen, DE
KNOBLOCH, Martin, DE
|
| (73) |
AbbVie Deutschland GmbH & Co. KG,
Mainzer Strasse 81, 65189 Wiesbaden,
DE
|
| (54) | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL-2 FAMILY INHIBITOR |
| PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL-2 FAMILY INHIBITOR |